Diabetes and obesity have become pressing health issues worldwide. Glucagon-like peptide-1 (GLP-1) receptor agonists, a class ...

Besides Mankind, Natco Pharma, Dr Reddy’s, Sun Pharma and others are already gearing up for launches of weight-loss drugs ...

The startling findings raise the possibility that the medicines, originally developed to treat diabetes, could one day be ...

Diabetes and obesity have become pressing health issues worldwide. Glucagon-like peptide-1 (GLP-1) receptor agonists, a class of medications widely used in the treatment of type 2 diabetes (T2D), have ...

It’s hard to watch television without seeing advertisements for compounded GLP-1 weight-loss drugs cheaper than the authentic ...

Shortages of Ozempic and Wegovy that have been in place for more than two years have been resolved, as supplies of obesity ...

Glucagon-like peptite-1 (GLP-1) receptor agonists, such as Wegovy and Ozempic, have taken the food industry by storm. With ...

We recently published a list of the 10 Oversold Pharma Stocks to Buy According to Analysts. In this article, we are going to take a look at where Novo Nordisk A/S (NYSE: NVO) stands against the other ...

Eli Lilly was second to the lucrative GLP-1 market for diabetes and obesity following its chief metabolic medicine rival Novo ...

There’s evidence that the demographic of people on the drugs overlaps with those who like to spend, a group some analysts ...

Elon Musk wants to cut funding for scientific research, but the weight loss drugs he promoted also came from government funded basic science.

Patients who have significant weight loss with anti-obesity medications after joint replacement show reductions in the risk for revision; however, caution on their use is urged as patients recover.